Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06574698
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-18
Brief Title:
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma A Prospective Single-Arm Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the efficacy of adding anti-GD2 immunotherapy Naxitamab at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None